The findings of both studies suggest that methylation at different promoter regions of the BDNF gene are implicated in MDD – however, one study evaluated exon I, whereas the other evaluated exon IV, which suggests that perhaps drug-induced methylation changes in different exons may or may not correlate with disease remission and/or response to treatment. This evidence concerns the gene BDNF and major depressive disorder.